SCHEMBL10169930

SCHEMBL10169930

CCC(C)N1CC(Oc2ccc(-c3c(-c4ccccc4Cl)noc3-c3ccc(O)cc3)cc2)C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
S1PR1 P21453 2/20 0.36
S1PR3 Q99500 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NR1H4 Q96RI1 4/20 0.35
PPARD Q03181 3/20 0.35
ALOX5 P09917 2/20 0.35
ALOX5AP P20292 2/20 0.35
USP7 Q93009 1/20 0.34
MAPT P10636 2/20 0.34
LMNA P02545 2/20 0.33
ESR1 P03372 1/20 0.33
HSP90AA1 P07900 2/20 0.33
ALDH1A1 P00352 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
FABP1 P07148 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9956577 0.99 PTGS1 (0.36) PTGS1PTGS2S1PR1S1PR3MEN1
SCHEMBL10169715 0.87 HSP90AA1 (0.39) PTGS1PTGS2S1PR1S1PR3NR1H4
Hydrochloric Acid SCHEMBL9955834 0.86 HSP90AA1 (0.39) PTGS1PTGS2S1PR1S1PR3NR1H4
SCHEMBL9956414 0.86 ESR1 (0.46) PTGS1PTGS2S1PR1S1PR3ALOX5
Hydrochloric Acid SCHEMBL9955635 0.85 ESR1 (0.45) PTGS1PTGS2S1PR1S1PR3ALOX5
SCHEMBL10169926 0.84 ESR1 (0.41) PTGS1PTGS2S1PR1S1PR3ALOX5
Hydrochloric Acid SCHEMBL9955889 0.84 ESR1 (0.40) PTGS1PTGS2S1PR1S1PR3ALOX5
SCHEMBL10169719 0.82 ESR1 (0.40) PTGS1PTGS2S1PR1S1PR3MEN1
Hydrochloric Acid SCHEMBL9957111 0.82 ESR1 (0.40) PTGS1PTGS2S1PR1S1PR3MEN1
SCHEMBL10169722 0.81 ESR1 (0.49) ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540361-B2 N-substituted azetidine derivatives MERCK SHARP & DOHME B.V. (NL) 2017-01-10 US disclosed
US-9540361-B2 N-substituted azetidine derivatives MERCK SHARP & DOHME B.V. (NL) 2017-01-10 US disclosed
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2016-05-12 US disclosed
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2016-05-12 US disclosed
WO-2012084711-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MSD OSS B.V. (NL) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES ESR2, ESR1, GPER1 PTGS1 314/4885PTGS2 448/4885S1PR1 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.